SCHEMBL6409209

SCHEMBL6409209

CC/C(Nc1ccc(CCNC)cc1)=C1/C(=O)Nc2cc(OC)c(OC)cc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 4/20 0.42
POLB P06746 2/20 0.41
ATM Q13315 1/20 0.41
MAPT P10636 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CHEK1 O14757 1/20 0.37
EGFR P00533 1/20 0.37
THRB P10828 1/20 0.37
CNR1 P21554 1/20 0.37
BRD4 O60885 2/20 0.36
BRD2 P25440 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
AURKA O14965 1/20 0.35
KDR P35968 1/20 0.35
AURKB Q96GD4 1/20 0.35
HTR1A P08908 1/20 0.34
HTR1D P28221 1/20 0.34
HTR1B P28222 1/20 0.34
HTR2A P28223 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6409220 1.00 RET (0.42) RETPOLBATMMAPTMEN1
SCHEMBL6330681 0.91 RET (0.41) RETPOLBMAPTMEN1KMT2A
SCHEMBL6330669 0.91 RET (0.41) RETPOLBMAPTMEN1KMT2A
SCHEMBL6336574 0.90 RET (0.43) RETPOLBATMMEN1KMT2A
SCHEMBL6336573 0.90 RET (0.43) RETPOLBATMMEN1KMT2A
SCHEMBL6331265 0.89 SMN1; SMN2 (0.43) RETPOLBMAPTMEN1KMT2A
SCHEMBL6331269 0.89 SMN1; SMN2 (0.43) RETPOLBMAPTMEN1KMT2A
SCHEMBL6329067 0.89 RET (0.42) RETATMMEN1KMT2ACHEK1
SCHEMBL6329081 0.89 RET (0.42) RETATMMEN1KMT2ACHEK1
SCHEMBL6337435 0.87 RET (0.41) RETCHEK1EGFRBRD4BRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments CCNE1, CDK1, CCNI RET 154/4885POLB 2055/4885ATM 735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.